Virtual ACC 2020 | Statins Could Also Protect Against Chemotherapy Cardiotoxicity

This retrospective study has shown a reduction in hospitalization for cardiac failure in patients who were already using statins receiving anthracycline and trastuzumab in the context of breast cancer.  

ACC 2020 Virtual | Las estatinas también podrían proteger la cardiotoxicidad de la quimioterapia

The study was to be presented during the ACC 2020 scientific sessions together with the World Congress of Cardiology. However, it had to be called off because of the COVID19 pandemic.

Despite the cardiac risk associated to chemotherapy, anthracycline and trastuzumab are essential to breast cancer treatment. The secret is protecting the heart against its adverse effects. 

Coming from small single-center studies, the evidence supporting statins might protect the heart is limited, yet enough to justify further prospective studies to determine whether statins are indeed effective, and also to understand the physiopathological mechanism behind it. 


Read also: TAVR in Small Annuli: Is There a Better Valve?


The study gathered data on women over 66 years of age, with no history of cardiac failure, who had been diagnosed with early stage breast cancer. The use of statins was defined as having a prescription dispensed in the year prior to chemotherapy. 

723 pairs of women treated with anthracyclines (mean age 69) and 399 treated with trastuzumab (mean age 71) were propensity-matched. 

Risk of hospitalization for cardiac failure resulted significantly lower in patients who had received statins prior to chemotherapy, both for patients treated with anthracyclines (HR 0.42, 0.22 a 0.82; p=0.01) and trastuzumab (HR 0.34, 0.14 a 0.82; p=0.02).


Read also: TAVR in Extremely Large Annuli: Different Patients Might Need Different Prostheses.


It is still early to recommend prior treatment with statins in this group of women since the available data is not enough. The link does exist, but the cause-effect relationship should be tested prospectively.

Original Title: Statins are associated with lower risk of heart failure after anthracycline and trastuzumab chemotherapy for early stage breast cáncer.

Reference: Bobrowski D. ACC 2020 virtual.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...